Molecularly guided therapy improves survival outcomes for patients with a cancer of unknown primary out on @JournalCancer A phase 2, open-label trial published in The Lancet demonstrated that molecularly guided therapy (MGT) significantly improved progression-free survival (PFS) in patients with newly diagnosed unfavorable cancer of unknown primary (CUP) compared to standard platinum-based chemotherapy. Patients with actionable molecular alterations who received targeted therapy had a 28% reduced risk of disease progression (hazard ratio, 0.72) and a median PFS of 8.1 months versus 4.7 months for those on chemotherapy. The study, known as CUPISCO, highlighted the potential of early comprehensive genomic profiling (CGP) in improving treatment outcomes, suggesting that CGP should be incorporated at initial diagnosis to offer personalized treatment options, including immunotherapy for patients with high tumor mutation burden. However, access to CGP remains limited globally. buff.ly/4fZbbDy @Aiims1742 @pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @heinrich_kat @Dr_Ivanoncologo

Agradecido por concesión junto a Tanya Knott del Premio Ennova Health en #BigData e Inteligencia Artificial #IA otorgado por @diariomedico @CFarmaceutico por diagnóstico de #cáncer de origen desconocido #CUP #TOD usando transcriptómica espacial #spatialbiology; trabajo apoyado por Sarah Jennifer Knott Foundation @SJK_Foundation